Search Results for: Pharma: Other News to Note
-
Other News To Note
T3D expects to reposition DB959 as a central nervous system therapy, using its neuroprotective potential to address multiple Alzheimer's disease pathologies, including neuroinflammation, neuronal cell loss, neurotransmitter deficits, tau neurofibrillary tangles and insulin resistance/lowered cerebral glucose metabolism...commercial rights to Bionect (hyaluronic acid sodium salt, 0.2 percent) in oncology markets from Innocutis Holdings LLC to concentrate on niche products for oncology and oncology -
Other News To Note
Madera Biosciences Inc., of San Diego, said it was awarded follow-on funding of $298,500 from the Alzheimer's Drug Discovery Foundation to further develop the firm's small-molecule drugs designed to clear accumulated beta-amyloid from the brain and thus halt or reverse the progression of Alzheimer's disease -
Other News To Note
Aphios Corp., of Woburn, Mass., said it entered joint research collaboration and commercialization agreements with Vivacell Biotechnology Espana SL, of Cordoba, Spain, to develop therapeutics for multiple sclerosis and other neurodegenerative diseases of the central nervous system...That is in contrast to some other antibiotics, such as linezolid (Zyvox), which causes drug interactions when taken with selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors...Zealand -
Other News To Note
In other news, Biolinerx said it signed an out-licensing agreement with Jiagsu chia-tai Tianqing Pharmaceutical Co...Biotie Therapies Corp., of Turku, Finland, obtained an exclusive option to acquire Neurelis Inc., of San Diego -
Other News To Note
Cardium Therapeutics Inc., of San Diego, held its annual meeting of stockholders and temporarily adjourned the meeting to allow additional time for stockholders to vote on two remaining issues related to a proposed reverse stock split and a charter amendment, which were favored by a majority of shares voted but which also require a majority of all outstanding shares, including unvoted shares...Regen BioPharma, of San Diego, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc., submitted -
Pharma: Other News To Note
Under priority review, the FDA aims to complete its review within an eight-month review cycle...Metreleptin, a recombinant analogue of human hormone leptin, was developed by San Diego-based Amylin Pharmaceuticals Inc., which was acquired in a joint buyout by BMS and AstraZeneca last year. (See BioWorld Today, July 3, 2012 -
Other News To Note
Biotie Therapies Corp., of Turku, Finland, obtained an exclusive option to acquire Neurelis Inc., of San Diego...Horizon Pharma Inc., of Deerfield, Ill., said in an SEC filing that it provided written notice to Mallinckrodt LLC, the pharmaceuticals business of Dublin, Ireland-based Covidien LLC, of the termination of the companies' co-promotion agreement dated June 14, 2012, effective 30 days after the date of such notice -
Other News To Note
AstraZeneca is planning to develop ISIS-ARRx broadly to treat patients under a variety of settings during the course of prostate cancer treatment, including both as a single agent and in combination therapy...Maxygen Inc., of Redwood City, Calif., said its board approved the liquidation and dissolution of the company, subject to shareholder approval, and plans to distribute all available cash to its shareholders after making reasonable provision for known and potential liabilities and other -
'JAK'ing Up Myelofibrosis; Sanofi's Phase III Data Solid
The Paris-based big pharma, which gained rights to JAK drug SAR302503 in its 2010 buyout of TargeGen Inc., reported solid top-line data from the Phase III study dubbed JAKARTA, showing that both dose groups of the drug hit the primary endpoint of reducing spleen volume...Phase I/II data reported by San Diego-based TargeGen prior to the Sanofi buyout also showed the potential of SAR302503 to reduce white blood cell count in patients with leukocytosis and reduce mutant cells responsible for causing -
Other News To Note
plc, of Dublin, Ireland, published a response to an offer made by Echo Pharma Acquisition Ltd. (Royalty Pharma) on May 2...Helsinn Healthcare SA, of Lugano, Switzerland, and Vifor Pharma, of Villars-sur-Glane, Switzerland, signed an exclusive license and distribution agreement for netupitant-palonosetron fixed-dose combination, an investigational Helsinn product for chemotherapy-induced nausea and vomiting, giving rights to Vifor to distribute the product in Switzerland, France, Spain, Portugal -
Other News To Note
In other news, Addex said dipraglurant demonstrated dose-dependent mGlu5 receptor occupancy in a nonhuman primate positron emission tomography study, showing the correlation between the plasma concentration of dipraglurant and occupancy of dipraglurant on mGlu5 receptors in the brain...Institut de Recherches Servier, of Paris, inked a nonexclusive collaboration to use the enhanced spine platform (ESP) technology developed by Afraxis Inc., of San Diego, to discover central nervous system (CNS) drugs -
Arena Yanks MAA, Falls on Belviq Launch Delay in U.S.
Allergan licensed rights to the Darpin technology from Molecular Partners AG for development in AMD and other eye diseases. (See BioWorld Today, Aug. 22, 2012.) And Eylea has fared well so far against Roche AG's Lucentis (ranibizumab), due to its lower cost and a label that calls for less frequent dosing, and even to cancer drug Avastin (bevacizumab), a cheaper, off-label alternative -
Other News To Note
In separate news, Hyperion said it exercised its option to acquire Buphenyl (sodium phenylbutyrate) tablets and powder, an FDA-approved therapy for the chronic management of the most prevalent UCDs, and Ammonul (sodium phenylacetate and sodium benzoate) injection, a hospital-based product used to treat UCD patients in hyperammonemic crisis, from Valeant Pharmaceuticals International Inc., of Montreal...The big pharma firm stated that it has opted to prioritize the fixed-ratio combination of Lantus -
Other News To Note
Institut de Recherches Servier, of Paris, inked a nonexclusive collaboration to use the enhanced spine platform (ESP) technology developed by Afraxis Inc., of San Diego, to discover central nervous system (CNS) drugs...Pfenex Inc., of San Diego, awarded Glide Pharma, of Oxford, UK, a subcontract to develop a solid formulation containing the recombinant protective antigen (rPA) from Bacillus anthracis expressed in Pfenex Expression Technology, suitable for delivery with the Glide SDI (solid dose -
Other News To Note
Celgene Corp., of Summit, N.J., said the European Committee for Medicinal Products for Human Use adopted a positive opinion for Revlimid (lenalidomide) for the treatment of patients with transfusion-dependent anemia due to low or intermediate-1 risk myelodsyplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate...Ligand Pharmaceuticals Inc., of San Diego, reported preclinical data showing highly targeted liver -
Other News To Note
EpiVax Inc., of Providence, R.I., and BioAtla LLC, of San Diego, formed a collaboration to incorporate EpiVax's immunogenicity screening technology, EpiMatrix, into BioAtla's antibody Express Humanization platform...Tranzyme Pharma Inc., of Research Triangle Park, N.C., and Ocera Therapeutics Inc., of San Diego, entered a definitive agreement under which Ocera will merge with a subsidiary of Tranzyme in an all-stock transaction -
Other News To Note
Net proceeds will be used to complete a Phase II Squalamine eye drop clinical trial for the wet form of age-related macular degeneration, to further the clinical development of the eye drops for the treatment of other neovascular ophthalmic disorders, to fund development of other pipeline molecules, and for general corporate purposes -
Other News To Note
La Jolla Pharmaceutical Co., of San Diego, said the FDA granted orphan designation to LJPC-6417 for fibrodysplasia ossificans progressiva (FOP...Santaris Pharma A/S, of Hoersholm, Denmark, said the European Patent Office issued minutes of the oral proceedings specifying the board of appeal's decision to maintain EP 1015469, the "Wengel" patent, with claims to amino- and thio-LNA nucleotides and oligonucleotides -
Other News To Note
Armgo Pharma Inc., of Tarrytown, N.Y., and the Muscular Dystrophy Association (MDA) said $1 million was awarded for preclinical work in support of an investigational new drug application for AMR201, an oral, small-molecule Rycal drug that has the potential to treat Duchenne's muscular dystrophy...In separate news, another Galapagos unit, Argenta, inked a deal with Boehringer Ingelheim GmbH, of Ingelheim, Germany, to apply its respiratory drug discovery services to an undisclosed target within -
Pharma: Other News To Note
Amylin Pharmaceutical Inc., of San Diego, (later acquired by Bristol-Myers Squibb Co. with help from AstraZeneca plc) is the subject of a three-defendant lawsuit along with Merck & Co...Pradax is used to prevent clotting in patients who suffer from atrial fibrillation
Category
Current Filters
- xSan Diego
Related Keywords
Categories
- x BioWorld Today (1185)
- x BioWorld International (145)
- x BioWorld Insight (6)
- x Bio Perspectives (6)